| Li, Huafang |
| Completed | 2 | 30 | RoW | Xiongdan Wan | Shanghai Mental Health Center | Major Depressive Disorder | 08/22 | 08/22 | | |
NCT06731868: Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia |
|
|
| Not yet recruiting | 1/2 | 120 | RoW | LPM3770164 sustained release tablet 5 mg, LY03015, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg, LPM3770164 sustained release tablet simulant, placebo | Luye Pharma Group Ltd. | Tardive Dyskinesia (TD) | 10/25 | 10/25 | | |
NCT05656274: A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects. |
|
|
| Recruiting | 1b | 48 | RoW | JS1-1-01, Placebo | Tasly Pharmaceutical Group Co., Ltd | Healthy Volunteers | 05/23 | 05/23 | | |
NCT05233657: A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule |
|
|
| Recruiting | 1 | 58 | RoW | JX11502MA, Placebo | Zhejiang Jingxin Pharmaceutical Co., Ltd. | Schizophrenia | 01/22 | 02/22 | | |
NCT05015192: Single Ascending Dose Study of NH102 in Healthy Subjects |
|
|
| Recruiting | 1 | 72 | RoW | NH102, H04, Placebo | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Depression | 04/22 | 04/22 | | |
NCT05238701: A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects |
|
|
| Completed | 1 | 104 | RoW | LPM3770164 sustained release tablet, LY03015, LPM3770164 sustained release tablet simulant, LY03015 simulant | Luye Pharma Group Ltd. | Huntington Disease, Tardive Dyskinesia | 11/23 | 11/23 | | |
NCT06216054: Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects |
|
|
| Completed | 1 | 40 | RoW | LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant | Luye Pharma Group Ltd. | Tardive Dyskinesia, Huntington Disease | 07/24 | 07/24 | | |
NCT06388551: A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 |
|
|
| Not yet recruiting | 1 | 60 | RoW | LY03017, LPM526000133 Fumarate Capsules, LY03017-Placebo | Luye Pharma Group Ltd. | Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia | 03/25 | 03/25 | | |
NCT06474650: Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets |
|
|
| Completed | 1 | 16 | RoW | LPM3770164 sustained release tablet, LY03015 | Luye Pharma Group Ltd. | Huntington Disease, Tardive Dyskinesia | 09/24 | 09/24 | | |
NCT06793995: Effect of Food and Age on the Pharmacokinetics of LY03017 |
|
|
| Not yet recruiting | 1 | 26 | RoW | LY03017 | Luye Pharma Group Ltd. | Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia | 10/25 | 10/25 | | |
NCT03672448: The China Longitudinal Aging Study of Cognitive Impairment |
|
|
| Recruiting | N/A | 10000 | RoW | Naturalistic observation, Normal Aging | Shanghai Mental Health Center | Mild Cognitive Impairment, Alzheimer Disease, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal, Depression, Anxiety | 11/23 | 11/23 | | |
NCT06182722: Association of Peripheral Immune Cells With Antidepressant Treatment Response |
|
|
| Recruiting | N/A | 90 | RoW | Mental assessments, Psychiatric rating scales | Shanghai Mental Health Center | Depressive Disorder, Genetic Change | 12/25 | 12/25 | | |
NCT05247593: A Study of Dayingpian Treating Bipolar Disorder |
|
|
| Recruiting | N/A | 308 | RoW | Dayingpian, conventional mood stabilizers | Shanghai Mental Health Center | Bipolar Disorder | 06/24 | 09/24 | | |
NCT02640911: An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia |
|
|
| Recruiting | N/A | 3000 | RoW | | Shanghai Mental Health Center | Schizophrenia | 05/30 | 05/33 | | |
NCT04518592: Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module. |
|
|
| Recruiting | N/A | 300 | RoW | | Shanghai Mental Health Center | Major Depressive Disorder | 09/24 | 09/24 | | |
